Piatkowska-Jakubas Beata, Mensah-Glanowska Patrycja, Salamańczuk Zoriana, Skotnicki Aleksander B
Katedra i Klinika Hematologii, Uniwersytet Jagielloński Collegium Medicum w Krakowie.
Przegl Lek. 2011;68(6):291-5.
Cytogenetic analysis of leukemic blasts has become a part of the standard diagnosis approach of acute myeloid leukemia patients. Chromosomal aberrations findings separate AML patients into three broad prognostic categories: favorable, intermediate and high risk. We analyzed retrospectively 179 adults with de novo acute myeloid leukemia (AML), younger than 60 years admitted to our Department between January 1999 and April 2009 to evaluate the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, disease free survival (DFS), and overall survival (OS). All patients received similar induction therapy. Median follow-up of 3.8 years for favorable cytogenetic group CR rate was 85%, 3-year DFS was 70% and 3-year OS was 65%, for intermediate group CR rate, 3-year DFS and 3-year OS were respectively: 64%, 43%, and 38%. Among high risk patient CR rate was 40%, 3-year DFS was 24%, 3-year OS was 17%. We conclude that cytogenetics is among the most useful factors in predicting attainment of CR, DFS, and long-term overall survival in adult de novo AML patients younger than 60 years.
白血病原始细胞的细胞遗传学分析已成为急性髓系白血病患者标准诊断方法的一部分。染色体异常结果将急性髓系白血病患者分为三大预后类别：良好、中等和高危。我们回顾性分析了1999年1月至2009年4月期间收入我院的179例年龄小于60岁的初发急性髓系白血病（AML）成年患者，以评估细胞遗传学异常对完全缓解（CR）率、无病生存期（DFS）和总生存期（OS）的预后影响。所有患者均接受了相似的诱导治疗。细胞遗传学良好组的中位随访时间为3.8年，CR率为85%，3年DFS为70%，3年OS为65%；中等组的CR率、3年DFS和3年OS分别为：64%、43%和38%。高危患者的CR率为40%，3年DFS为24%，3年OS为17%。我们得出结论，细胞遗传学是预测年龄小于60岁的初发成年AML患者达到CR、DFS和长期总生存期的最有用因素之一。
